Tovoli Francesco, Negrini Giulia, Bolondi Luigi
Department of Medical & Surgical Sciences, Alma Mater Studiorum-University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Hepat Oncol. 2016 Apr;3(2):119-136. doi: 10.2217/hep-2015-0006. Epub 2016 Mar 23.
Hepatocellular carcinoma is one of the most common malignancies and represents a unique challenge for physicians and patients. Treatment patterns are not uniform between areas despite efforts to promote a common protocol. Even if most hepatologists worldwide adopt the Barcelona Clinic Liver Cancer staging system, Asian and North American physicians are also independently making an effort to expand the indications of each treatment, combining therapies for better outcomes. Also, new therapeutic techniques have emerged and an increasing number of studies are trying to include these paradigm shifts into newer treatment guidelines. Controversial and diverging points in the current international guidelines are emphasized and discussed. Unanswered questions are also analyzed to identify the most needed and promising future perspectives.
肝细胞癌是最常见的恶性肿瘤之一,对医生和患者来说都是一项独特的挑战。尽管一直在努力推广统一的治疗方案,但不同地区的治疗模式并不统一。即使全球大多数肝病专家都采用巴塞罗那临床肝癌分期系统,亚洲和北美医生也在各自努力扩大每种治疗方法的适应证,联合多种疗法以取得更好的治疗效果。此外,新的治疗技术不断涌现,越来越多的研究试图将这些范式转变纳入更新的治疗指南中。本文强调并讨论了当前国际指南中存在争议和分歧的要点。还对未解决的问题进行了分析,以确定最迫切需要且最有前景的未来研究方向。